Roanna Ruiz
Stock Analyst at Leerink Partners
(1.41)
# 3,887
Out of 5,049 analysts
59
Total ratings
35.9%
Success rate
-9.91%
Average return
Main Sectors:
Stocks Rated by Roanna Ruiz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IBIO iBio, Inc. | Initiates: Outperform | $2 | $1.39 | +43.88% | 1 | Oct 17, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $7 → $9 | $7.71 | +16.73% | 7 | Aug 19, 2025 | |
| AKBA Akebia Therapeutics | Initiates: Outperform | $7 | $2.01 | +248.26% | 1 | Apr 28, 2025 | |
| CRMD CorMedix | Initiates: Outperform | $18 | $10.78 | +66.98% | 1 | Mar 7, 2025 | |
| LXRX Lexicon Pharmaceuticals | Downgrades: Market Perform | $1 | $1.43 | -30.07% | 1 | Mar 4, 2025 | |
| VIR Vir Biotechnology | Maintains: Outperform | $18 → $20 | $5.12 | +290.63% | 4 | Jan 13, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Outperform | $26 → $27 | $8.20 | +229.47% | 4 | Jan 13, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Outperform | $12 → $13 | $6.13 | +112.07% | 3 | Oct 25, 2024 | |
| ARDX Ardelyx | Initiates: Outperform | $14 | $5.65 | +147.79% | 1 | Apr 5, 2024 | |
| UTHR United Therapeutics | Initiates: Outperform | $330 | $454.00 | -27.31% | 1 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $58 | $60.30 | -3.81% | 1 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $25 | $73.06 | -65.78% | 1 | Apr 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | $49 | $10.80 | +353.70% | 10 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $6 | $3.25 | +84.62% | 6 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $37.05 | -48.72% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $120 | $53.69 | +123.51% | 3 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $75 → $50 | $7.10 | +604.23% | 7 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $40 | $15.67 | +155.26% | 6 | Oct 19, 2022 |
iBio, Inc.
Oct 17, 2025
Initiates: Outperform
Price Target: $2
Current: $1.39
Upside: +43.88%
Xeris Biopharma Holdings
Aug 19, 2025
Maintains: Outperform
Price Target: $7 → $9
Current: $7.71
Upside: +16.73%
Akebia Therapeutics
Apr 28, 2025
Initiates: Outperform
Price Target: $7
Current: $2.01
Upside: +248.26%
CorMedix
Mar 7, 2025
Initiates: Outperform
Price Target: $18
Current: $10.78
Upside: +66.98%
Lexicon Pharmaceuticals
Mar 4, 2025
Downgrades: Market Perform
Price Target: $1
Current: $1.43
Upside: -30.07%
Vir Biotechnology
Jan 13, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $5.12
Upside: +290.63%
ARS Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $26 → $27
Current: $8.20
Upside: +229.47%
Aquestive Therapeutics
Oct 25, 2024
Maintains: Outperform
Price Target: $12 → $13
Current: $6.13
Upside: +112.07%
Ardelyx
Apr 5, 2024
Initiates: Outperform
Price Target: $14
Current: $5.65
Upside: +147.79%
United Therapeutics
Feb 5, 2024
Initiates: Outperform
Price Target: $330
Current: $454.00
Upside: -27.31%
Aug 15, 2023
Initiates: Outperform
Price Target: $58
Current: $60.30
Upside: -3.81%
Apr 11, 2023
Initiates: Market Perform
Price Target: $25
Current: $73.06
Upside: -65.78%
Feb 9, 2023
Reiterates: Market Perform
Price Target: $49
Current: $10.80
Upside: +353.70%
Jan 27, 2023
Maintains: Market Perform
Price Target: $8 → $6
Current: $3.25
Upside: +84.62%
Dec 20, 2022
Initiates: Outperform
Price Target: $19
Current: $37.05
Upside: -48.72%
Nov 15, 2022
Maintains: Outperform
Price Target: $110 → $120
Current: $53.69
Upside: +123.51%
Nov 3, 2022
Maintains: Market Perform
Price Target: $75 → $50
Current: $7.10
Upside: +604.23%
Oct 19, 2022
Maintains: Market Perform
Price Target: $60 → $40
Current: $15.67
Upside: +155.26%